Edesa Biotech
EDSA
24 hedge funds and large institutions have $617K invested in Edesa Biotech in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
9% more funds holding
Funds holding: 22 → 24 (+2)
0.56% less ownership
Funds ownership: 1.86% → 1.3% (-0.56%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
89% less capital invested
Capital invested by funds: $5.51M → $617K (-$4.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$113K |
| 2 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$43K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.58K |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.74K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$912K |
| 2 |
Renaissance Technologies
New York
|
-$77K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$73.4K |
| 4 |
Two Sigma Investments
New York
|
-$33K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$12.6K |
EDSA Hedge Fund Activity: Q2 2022 in Review
24 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2022, worth a combined $617K — down 89% from $5.51M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EDSA positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $113K. The largest seller was Armistice Capital, cutting an estimated $912K.
- 24 institutional investors held Edesa Biotech (EDSA) as of Q2 2022, up from 22 in Q1 2022.
- Funds reported $617K of Edesa Biotech stock for Q2 2022, down 89% quarter-over-quarter.
- 3 funds opened new Edesa Biotech positions in Q2 2022 and 1 closed out, a net change of +2 holders.
- The largest Edesa Biotech buyer in Q2 2022 was Millennium Management, an estimated $113K added.
- The largest Edesa Biotech seller in Q2 2022 was Armistice Capital, an estimated $912K sold.
Based on aggregated 13F filings for Q2 2022.